APLMW Company Profile and Key Details

The stock is currently trading near its 52-week low $0.01 and $0.03. With a market capitalization of about $169.97 million, Apollomics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~2.07). Key stats such as the average daily volume over the past year has been around 81.19 thousand shares, volume is running light vs its 52-week average. Headquartered in Foster City, CA, Apollomics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Hung-Wen Chen, the company employs approximately 14 people and listed since March 30, 2023. Apollomics, Inc. functions as a clinical-phase biotechnology enterprise, concentrating its efforts on discovering and advancing novel cancer treatments to meet crucial, underserved patient requirements.

Average 10-day trading volume of 15.25 thousand shares is below the 3-month average of 98.15 thousand, indicating normal recent market interest.

Apollomics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $6.16. This means the shares are trading below this model’s fair value.

Valuation shows Apollomics, Inc. trading at a premium to the broader market with a P/E of -3.22.

Our AI price prediction model suggests that Apollomics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Apollomics, Inc. trades at a P/E ratio of -3.22, slightly below the S&P 500 average, with a price-to-sales ratio of 6.3 and a price-to-book ratio of -3.22 indicating negative book value, which may reflect financial stress. The P/FCF stands at -5.16, also below market averages.